Physician profile
Benjamin C Pease
NPI 1952308082
$1,693.88
in general payments reported to CMS, 2019-2025
29 companies · $534 in 2025
The $534 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134 · 2020: $171 · 2021: $241 · 2022: $157 · 2023: $173 · 2024: $284 · 2025: $534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $991.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $991.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $265.04 | 2024-2025 | Inspire |
| Glaxosmithkline, LLC. | $165.23 | 2019-2025 | Nucala, Trelegy Ellipta |
| Intersect Ent, INC. | $163.44 | 2021 | |
| Aerin Medical INC. | $130.94 | 2022-2025 | |
| Genentech USA, INC. | $121.18 | 2022-2025 | Xolair |
| Acclarent, INC | $88.84 | 2019-2023 | Trudi Nav Cable, Relieva Tract |
| Grifols USA, LLC | $81.72 | 2025 | Prolastin-C Liquid |
| Genzyme Corporation | $72.48 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.69 | 2020-2022 | |
| Smith+Nephew, INC. | $54.65 | 2025 | Tula, Halo, Ent Sinus |
| Astrazeneca Pharmaceuticals LP | $48.44 | 2019-2023 | Breztri |
| Amgen INC. | $48.14 | 2023-2025 | Tezspire |
| Philips North America LLC | $41.23 | 2020-2025 | Patient Interface Software |
| Takeda Pharmaceuticals U.S.A., INC. | $35.88 | 2021-2025 | Glassia |
| Regeneron Healthcare Solutions, INC. | $31.77 | 2024 | Dupixent |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $28.72 | 2021-2022 | |
| Abbvie INC. | $28.00 | 2023 | |
| Jazz Pharmaceuticals INC. | $27.52 | 2022-2023 | Xywav |
| Organogenesis INC. | $25.84 | 2022 | |
| Checkpoint Surgical, INC | $25.45 | 2024 | Checkpoint Stimulators |
| Merck Sharp & Dohme LLC | $23.54 | 2023 | |
| Integra Lifesciences Corporation | $20.19 | 2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Kerecis Limited | $19.64 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Sunovion Pharmaceuticals INC. | $19.23 | 2020 | |
| Apria Healthcare LLC | $16.55 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $16.40 | 2024 | Uptravi, Opsumit |
| Insmed, INC. | $14.80 | 2025 | Arikayce |
| Novartis Pharmaceuticals Corporation | $13.01 | 2023 | |
| Allergan, INC. | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Pease listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.